300244 迪安诊断
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,218,159-9.12%13,408,32020,282,46913,082,61310,649,162
减:营业总成本5,720,137-3.88%12,243,28216,603,82111,084,4098,862,648
    其中:营业成本4,496,204-1.70%9,213,38312,745,8118,076,9496,578,706
               财务费用98,818-14.41%220,608298,236217,479195,875
               资产减值损失(2,632)296.51%(16,738)(624,025)(272,189)(475,247)
公允价值变动收益(16,152)-607.81%(727)(56,236)83,354(2,586)
投资收益4,965-95.20%(17,596)48,78755,33873,148
    其中:对联营企业和合营企业的投资收益3,511-843.46%(6,722)26,76339,78520,783
营业利润247,844-68.21%842,1832,822,6091,837,9351,320,311
利润总额246,440-68.03%798,3262,543,5621,790,9971,317,395
减:所得税费用73,806-53.75%216,735681,092307,396247,461
净利润172,635-71.76%581,5911,862,4701,483,6011,069,934
减:非控股权益100,888-36.15%274,130428,279320,717267,002
股东净利润71,747-84.17%307,4611,434,1911,162,884802,933

市场价值指针
每股收益 (元) *0.115-84.05%0.4922.3021.8741.294
每股派息 (元) *0.650--0.0600.2000.1350.130
每股净资产 (元) *11.850-4.28%12.06911.8819.4167.572
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容